[HTML][HTML] Notch signaling pathway: architecture, disease, and therapeutics
B Zhou, W Lin, Y Long, Y Yang, H Zhang… - Signal transduction and …, 2022 - nature.com
The NOTCH gene was identified approximately 110 years ago. Classical studies have
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
[HTML][HTML] Patient-derived xenograft models in cancer therapy: technologies and applications
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
SJ Bagley, M Logun, JA Fraietta, X Wang, AS Desai… - Nature Medicine, 2024 - nature.com
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …
[HTML][HTML] Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
Multidimensional control of therapeutic human cell function with synthetic gene circuits
Synthetic gene circuits that precisely control human cell function could expand the
capabilities of gene-and cell-based therapies. However, platforms for developing circuits in …
capabilities of gene-and cell-based therapies. However, platforms for developing circuits in …
[HTML][HTML] Modular design of synthetic receptors for programmed gene regulation in cell therapies
I Zhu, R Liu, JM Garcia, A Hyrenius-Wittsten, DI Piraner… - Cell, 2022 - cell.com
Synthetic biology has established powerful tools to precisely control cell function.
Engineering these systems to meet clinical requirements has enormous medical …
Engineering these systems to meet clinical requirements has enormous medical …
Next-generation CAR T-cell therapies
RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
[HTML][HTML] The Notch signaling pathway: a potential target for cancer immunotherapy
Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …